Welcome to our dedicated page for Tenaris S. A. news (Ticker: $TS), a resource for investors and traders seeking the latest updates and insights on Tenaris S. A. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tenaris S. A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tenaris S. A.'s position in the market.
Tenaris S.A. shareholders approved all resolutions at the annual and extraordinary general meetings, including annual dividend declaration and the appointment of new directors. The Company's 2023 reports were acknowledged, and the share capital was reduced following a share buyback program.
Tenaris S.A. completed the second tranche of its Share Buyback Program, purchasing 16,367,003 ordinary shares for €277,137,521. The company now holds 34,146,305 shares in treasury, equal to 2.89% of the total issued share capital.
